16|Week Results from Phase 3 Clinical Trials

16-Week Results from Phase 3 Clinical Trials (Measure Up 1 and 2)

Upadacitinib therapy resulted in rapid, sustained improvements in PROs measuring symptom burden and QoL in adults and adolescents with moderate-to-severe AD.

Efficacy and safety of lebrikizumab in moderate-to-severe atopic ...

... week results of two randomized double-blinded placebo-controlled phase III trials ... Clinical Trial, Phase III. MeSH terms. Adolescent; Adult ...

Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic ...

We conducted two identically designed, 52-week, randomized, double-blind, placebo-controlled, phase 3 trials; both trials included a 16-week ...

Lutikizumab Showed Positive Results in a Phase 2 Trial of Adults ...

... clinical program for lutikizumab in HS to Phase 3." This study was a 16-week, Phase 2, randomized, double-blind, parallel group, placebo ...

Topline results from Boehringer's Phase III IPF Study

Full efficacy and safety data from the trial will be presented in the first half of 2025. Boehringer Ingelheim will submit a new drug ...

AbbVie Announces Positive Topline Results from Phase 3 TEMPO-1 ...

The TEMPO-1 trial also met the key secondary endpoint, demonstrating a statistically significant and clinically meaningful improvement in motor ...

Secukinumab in moderate-to-severe hidradenitis suppurativa ...

... 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials. Prof Alexa B Kimball, MD.

Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis

The primary outcome was the proportion of patients who had both a score of 0 or 1 (clear or almost clear) on the Investigator's Global ...

Bristol Myers Squibb Provides Update on the First Phase 3 ...

YELLOWSTONE is a Phase 3, multicenter clinical trial program consisting of two 12-week induction studies, a 52-week maintenance study and a 264- ...

EMERGE and ENGAGE Topline Results: Two Phase 3 Studies to ...

... Week 16 in ITT population; cDifference vs placebo at Week 78. Negative ... clinical studies. Summary of aducanumab Phase 3 topline results. AE, adverse ...

Efficacy and Safety of Xanomeline-Trospium Chloride in ...

Findings In this phase 3, double-blind, randomized, placebo-controlled trial in 256 people with schizophrenia, xanomeline-trospium was ...

Deucravacitinib versus placebo and apremilast in moderate to ...

Here, in a pivotal phase 3 study, deucravacitinib was shown to be superior to both placebo and apremilast for the treatment of patients with ...

FDAAA 801 and the Final Rule - ClinicalTrials.gov

Who is responsible for registering trials and submitting results? The responsible party for an applicable clinical trial (ACT) must register ...

Ionis announces positive topline results from Phase 3 OASIS-HAE ...

The Phase 3 OASIS-Plus open-label extension (OLE) study is a 53-week global, multicenter study of subcutaneous injections of donidalorsen administered every ...

Phases of clinical research - Wikipedia

Once a drug has proved satisfactory after Phase III trials, the trial results are usually combined into a large document containing a comprehensive ...

Bulevirtide monotherapy in patients with chronic HDV: Efficacy and ...

... results through week 96 from a phase III randomized trial. Heiner Wedemeyer ... weeks treatment in phase II and III clinical trials for chronic hepatitis delta.

Vertex Advances Inaxaplin (VX-147) into Phase 3 Portion of ...

Inaxaplin (VX-147) has advanced into the Phase 3 portion of the global Phase 2/3 pivotal clinical trial in APOL1-mediated kidney disease (AMKD).

Lilly's phase 2 retatrutide results published in The New England ...

Lilly to further investigate retatrutide for the treatment of obesity in the TRIUMPH phase 3 clinical program. INDIANAPOLIS , ... Longer duration phase 3 ...

two randomised, double-blind, placebo-controlled, phase 3 studies

ELEVATE UC 12 independently assessed induction at week 12. The primary efficacy endpoints were the proportion of patients with clinical ...

Apellis and Sobi Announce Positive Topline Results from Phase 3 ...

The study met the primary endpoint, demonstrating a statistically significant and clinically meaningful 68% (p<0.0001) proteinuria reduction ( ...